Prokidney (PROK) Preferred Stock Liabilities (2021 - 2022)
Prokidney's (PROK) quarterly Preferred Stock Liabilities came in at $250.4 million in Q2 2022, little changed quarter-over-quarter from $250.0 million in Q1 2022.
Powered by 
Analysis
Prokidney (PROK) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Prokidney (PROK) has reported Preferred Stock Liabilities for 2 consecutive years, with $250.4 million the latest figure, recorded in Q2 2022.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $250.4 million in Q2 2022; TTM through Jun 2022 was $250.4 million, a N/A change from a year earlier, with the FY2021 full-year figure at $250.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $250.4 million for Q2 2022 at Prokidney, roughly flat from $250.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $250.4 million in Q2 2022 and troughed at $250.0 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 250.37 Mn |
| Mar 31, 2022 | 250.00 Mn |
| Dec 31, 2021 | 250.01 Mn |
| Sep 30, 2021 | 250.00 Mn |